Glenmark launches fixed-dose triple therapy for COPD

New Delhi, Nov 25 (PTI) Glenmark Pharmaceuticals on Tuesday said it has launched the world's first nebulised, fixed-dose triple therapy for the treatment of chronic obstructive pulmonary disease.

Nebzmart GFB Smartules and Airz FB Smartules combine three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control, the Mumbai-based drug maker said in a regulatory filing.

As a single, easy-to-use nebulised therapy, it minimises the burden of multiple medications, it added.

This marks a breakthrough as a new standard of care for COPD patients, especially those who struggle with using metered dose inhalers or dry powder inhalers, the company said.

"This milestone reinforces Glenmark's position as a front-runner in respiratory innovation and our commitment to making advanced, affordable, and accessible solutions for patients," Glenmark Pharmaceuticals President & Business Head India Formulations Alok Malik said.

In a clinical study conducted in India, the nebulised triple therapy demonstrated rapid improvement in lung function and better control of breathlessness (dyspnea) among patients, the drug maker said.

"This launch represents a significant advancement in the management of COPD and demonstrates our focus on strengthening global respiratory leadership," Glenmark Pharmaceuticals Global Head of Clinical Development Monika Tandon said.

Shares of Glenmark were trading 2.09 per cent up at Rs 1,879.60 apiece on the BSE. PTI MSS SHW